Recent News

• 03.06.2025 - Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
• 03.06.2025 - Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
• 01.13.2025 - 8-K - Current report filing
• 01.08.2025 - 8-K - Current report filing
• 01.08.2025 - 8-K - Current report filing
• 01.08.2025 - Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
• 12.31.2024 - 8-K - Current report filing
• 12.31.2024 - Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
• 11.13.2024 - 8-K - Current report filing
• 11.13.2024 - 10-Q - Quarterly report pursuant to Section 13 or 15(d)

Recent Filings

• 01.13.2025 - EX-99.1 EX-99.1
• 01.13.2025 - 8-K Current report
• 01.08.2025 - 8-K Current report
• 01.08.2025 - EX-99.1 EX-99.1
• 12.31.2024 - 8-K Current report
• 12.31.2024 - EX-99.1 EX-99.1
• 11.13.2024 - 8-K Current report
• 11.13.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]